Loading clinical trials...
Loading clinical trials...
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Teres Bio, Inc.
NCT07223697 · Atopic Dermatitis
NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more
NCT02504853 · Food Allergy, Loeys-Dietz Syndrome, and more
NCT07355075 · Eczema Atopic Dermatitis, Eczema, and more
NCT04455906 · Atopic Dermatitis
Teres Bio site 05
Scottsdale, Arizona
Teres Bio Site 04
Encinitas, California
Teres Bio Site 12
North Miami Beach, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions